Neurocrine Biosciences, Inc.
0K6R.L
Get informed when a big investor buys or sells
+ FollowMarket Cap$14.32B
Close$
$332.10
145.7% upside
Current Fair Value
145.7% upsideUndervalued by 145.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $14.32 Billion |
|---|---|
| Enterprise Value | $14.72 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $4.81 |
| Beta | 0.39 |
| Outstanding Shares | 101,000,000 |
Return
| Return on Equity | 17.68% |
|---|---|
| Return on Assets | 13.16% |
| Return on Invested Capital | 17.56% |
Valuation & Multiples
| P/E Ratio | 20.2 |
|---|---|
| PEG | 58.86 |
| Price to Sales | 4.1 |
| Price to Book Ratio | 3.47 |
| Enterprise Value to Revenue | 4.36 |
| Enterprise Value to EBIT | 18.7 |
| Enterprise Value to Net Income | 20 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.1 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
July 30, 2026
EPS Estimate
$1.65
Average shareholder expectationRevenue Estimate
$891.16 M
Average shareholder expectationNext Earnings Call
Expected Date
October 28, 2026
EPS Estimate
$1.91
Average shareholder expectationRevenue Estimate
$1.04 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Neurocrine Biosciences, Inc.
2,000 employees
CEO: Kevin Gorman Neurocrine Biosciences, Inc. is a biopharmaceutical company dedicated to the research, development, and commercialization of innovative therapies for a range of neurological, endocrine, and psychiatric conditions. Its established portfol...